IP Library › Granted Patent US 12,514,819
Granted Patent B2
US 12,514,819 · App. 18/308,841 · Granted Jan 6, 2026

Colchicine drug-to-drug interactions

Inventors: Indu Muni (North Reading, MA); Naomi Vishnupad (Reading, MA)
Assignee: RxOMEG Therapeutics LLC
A61K9/08A61K9/0053A61K9/0095A61K31/165A61K31/403A61K31/4422A61K31/4709A61K31/496A61K47/02A61K47/12A61K47/36A61P19/02A61P29/00A61P31/00A61K47/10A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,819
App. No.
18/308,841
Granted
Jan 6, 2026
Kind
B2
Abstract

The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

Claims (8)

1 . A method of treating a colchicine sensitive disorder, comprising orally co-administering a pharmaceutical composition comprising a liquid colchicine solution and a CYP3A4 inhibitor to a human subject having a colchicine sensitive disorder in an effective amount to treat the disorder, wherein the liquid colchicine solution comprises 0.01-1.0 mg/ml colchicine, 0.1-0.3% w/v of anhydrous citric acid, 0.8-1.6% w/v of dibasic sodium phosphate heptahydrate, 0.1-0.2% w/v of a thickening agent, a preservative, and water, and wherein the colchicine sensitive disorder is selected from the group consisting of gout, familial Mediterranean fever (FMF), pericarditis, Behçet's disease, atrial fibrillation, amyloidosis, calcium pyrophosphate deposition disease (pseudogout), cirrhosis of the liver, and sarcoid arthritis.

2 . The method of claim 1 , wherein the CYP3A4 inhibitor is a posaconazole.

3 . The method of claim 2 , wherein the dose of posaconazole is 300-600 mg/dose/day.

4 . The method of claim 2 , wherein the dose of the liquid colchicine solution is reduced to 2.5 mL/day or lower when coadministered with posaconazole.

5 . The method of claim 2 , wherein there is a 2-6 fold increase in colchicine blood levels when posaconazole is co-administered with the liquid colchicine solution.

6 . The method of claim 1 , wherein the CYP3A4 inhibitor is amlodipine besylate.

7 . The method of claim 6 , wherein the dose of amlodipine besylate is 5-10 mg/dose/day.

8 . The method of claim 6 , wherein there is no significant effect on colchicine blood levels when the liquid colchicine solution is taken in conjunction with amlodipine besylate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2023
From: MUNI, INDU; VISHNUPAD, NAOMI
To: RXOMEG THERAPEUTICS LLC
Reel/Frame 064351/0330 →
Continuity (5)
Continuation 16544607 · Aug 19, 2019
Continuation 16155571 · Oct 9, 2018
Continuation 15848498 · Dec 20, 2017
Continuation 15848498 · Dec 20, 2017
Related Publication 20230330016A1 · Oct 19, 2023
References Cited (78)
US 5668154A · Fink et al. · 1997 [cited by applicant]
US 6140359A · Carver et al. · 2000 [cited by applicant]
US 7601758B1 · Davis · 2009 [cited by applicant]
US 7619004B1 · Davis · 2009 [cited by applicant]
US 7820681B1 · Davis · 2010 [cited by applicant]
US 7906519B2 · Davis · 2011 [cited by applicant]
US 7915269B2 · Davis · 2011 [cited by applicant]
US 7935731B2 · Davis · 2011 [cited by applicant]
US 7964647B2 · Davis et al. · 2011 [cited by applicant]
US 7964648B2 · Davis · 2011 [cited by applicant]
US 7981938B2 · Davis · 2011 [cited by applicant]
US 8093297B2 · Davis · 2012 [cited by applicant]
US 8097655B2 · Davis · 2012 [cited by applicant]
US 8440722B2 · Davis · 2013 [cited by applicant]
US 8927607B1 · Ducharme · 2015 [cited by applicant]
US 9555029B2 · Ducharme · 2017 [cited by applicant]
US 9907751B2 · Muni et al. · 2018 [cited by applicant]
US 10226423B1 · Muni et al. · 2019 [cited by applicant]
US 10383820B2 · Muni et al. · 2019 [cited by applicant]
US 10383821B2 · Muni et al. · 2019 [cited by applicant]
US 11672759B2 · Muni et al. · 2023 [cited by applicant]
US 12274751B2 · Muni et al. · 2025 [cited by applicant]
US 20030055029A1 · D'Amato et al. · 2003 [cited by applicant]
US 20050153946A1 · Hirsh et al. · 2005 [cited by applicant]
US 20090093548A1 · Mathew et al. · 2009 [cited by applicant]
US 20100179169A1 · Davis · 2010 [cited by applicant]
US 20110229564A1 · Desai et al. · 2011 [cited by applicant]
US 20130172368A1 · Roberts et al. · 2013 [cited by applicant]
US 20130274331A1 · Saha · 2013 [cited by examiner]
US 20140107213A1 · Davis · 2014 [cited by applicant]
US 20150057359A1 · Ducharme · 2015 [cited by applicant]
US 20150094317A1 · Ducharme · 2015 [cited by applicant]
US 20150094318A1 · Ducharme · 2015 [cited by applicant]
US 20150094322A1 · Riel et al. · 2015 [cited by applicant]
US 20150094375A1 · Ducharme · 2015 [cited by applicant]
US 20150164831A1 · Roberts et al. · 2015 [cited by applicant]
US 20150196513A1 · Nidorf · 2015 [cited by applicant]
US 20150196514A1 · Nidorf · 2015 [cited by applicant]
US 20150290325A1 · Kashi et al. · 2015 [cited by applicant]
US 20160354396A1 · Mahoney et al. · 2016 [cited by applicant]
US 20170258715A1 · Muni et al. · 2017 [cited by applicant]
US 20180092841A1 · Muni et al. · 2018 [cited by applicant]
US 20180098938A1 · Muni et al. · 2018 [cited by applicant]
US 20180117023A1 · Charles · 2018 [cited by examiner]
US 20190183793A1 · Muni et al. · 2019 [cited by applicant]
US 20190183794A1 · Muni et al. · 2019 [cited by applicant]
US 20200038322A1 · Muni et al. · 2020 [cited by applicant]
US 20200108147A1 · Muni et al. · 2020 [cited by applicant]
CN 101450072A · 2009 [cited by applicant]
CN 102872181A · 2013 [cited by applicant]
CN 105056131A · 2015 [cited by applicant]
WO 2008021666A2 · 2008 [cited by applicant]
WO 2009133431A1 · 2009 [cited by applicant]
WO 2013149109A1 · 2013 [cited by applicant]
WO 2017156392A1 · 2017 [cited by applicant]
WO 2018200143A2 · 2018 [cited by applicant]
U.S. Appl. No. 16/707,093, filed Dec. 9, 2019, Muni et al. [cited by applicant]
PCT/US2017/021777, Jun. 21, 2017, International Search Report and Written Opinion. [cited by applicant]
PCT/US2017/021777, Sep. 20, 2018, International Preliminary Report on Patentability. [cited by applicant]
PCT/US2018/066943, Apr. 3, 2019, International Search Report and Written Opinion. [cited by applicant]
PCT/US2018/066943, Jul. 2, 2020, International Prelimiary Report on Patentability. [cited by applicant]
EP17764180, Oct. 11, 2019, Extended European Search Report. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2017/021777 mailed Jun. 21, 2017. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2017/021777 mailed Sep. 20, 2018. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2018/066943 mailed Apr. 3, 2019. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2018/066943 mailed Jul. 2, 2020. [cited by applicant]
Extended European Search Report for Application No. EP17764180 mailed Oct. 11, 2019. [cited by applicant]
[No Author Listed], Colchicine Injection, USP. Bedford Laboratories. 1999. 2 pages. [cited by applicant]
[No Author Listed], Colchicine Product Information. Cayman Chemicals. Dec. 5, 2011. 1 page. [cited by applicant]
[No Author Listed], Colchicine Product Information. Sigma-Aldrich, Inc. 2003. 2 pages. [cited by applicant]
Artursson et al., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. Mar. 1, 2001;46(1-3):27-43. Review. [cited by applicant]
Habib et al., Influence of certain additives on the photostability of colchicine solutions+. Drug Development and Industrial Pharmacy. 1989; 15(11):1905-9. [cited by applicant]
Krishna et al., Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther. Feb. 2009;31(2):286-… [cited by applicant]
Rask et al., Cochicine use in 6000 patients with disk disease & other related resistantly-painful spinal disorders. J of Neurolog & Orthopaedic Medicine & Surgery. Dec. 1989; 10(4):291-8. [cited by applicant]
Shen et al., Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int J Nanomedicine. 2011;6:1237-43. doi: 10.2147/IJN.S20903. Epub Jun. 20, 2011. [cited by applicant]
Stewart et al., Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res. May 1995;12(5):693-9. [cited by applicant]
Yee, In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth. Pharm Res. 1997; 14(6):763-6. [cited by applicant]
Yu et al., Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. Jul. 2002;19(7):921-5. [cited by applicant]